The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial glucose reaches a prespecified low level. It is the only sensor-augmented insulin pump available in the US with this capability.
The MiniMed 530G system is approved in the US for patients ≥16 years old. It has been available in Europe as the Paradigm Veo since 2009. When interstitial glucose reaches a preset low-glucose threshold, an alert sounds and the pump automatically stops insulin delivery. After 2 hours, the insulin infusion starts again automatically, but the patient can override the suspension and restart insulin delivery at any time. The MiniMed 530G system, including the Enlite sensor and threshold suspend feature, costs about $7000, according to the manufacturer.
MiniMed 530G: An Insulin Pump With Low-Glucose Suspend Automation. JAMA. 2015;313(15):1568. doi:10.1001/jama.2015.2917
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: